Fluorescence confocal microscopy (FCM) represents a novel diagnostic technique able to provide real-time histological images from non-fixed specimens. As a consequence of its recent developments, FCM is gaining growing popularity in urological practice.
1. Introduction
Fluorescence confocal microscopy (FCM) is an imaging technique that provides real-time digital images of fresh tissue, without the need for further conventional pathology. It allows real-time microscopic examination with the high-resolution visualization of cells and structures.
Confocal microscopy was first described by Marvin Minsky in 1957
[1]. The key to confocal approach is the elimination of out-of-focus light (also known as flare) by scanning a point source of light across the specimen and using a pinhole to eliminate the out-of-focus light from the detector. When compared to a conventional wide field light microscope, the confocal microscope provides an increase in both the maximum lateral resolution (0.5 μm vs. 0.25 μm) and the maximum axial resolution (1.6 μm vs. 0.7 μm)
[2].
It can be used in reflectance (RCM) or fluorescence mode (FCM): RCM is based on the reflection of light from different components of cellular structures, while FCM involves the visualisation of fluorophores to characterise cellular details. FCM harnesses external dyes to obtain fluorescence contrast. To date, the most widely used is Acridine Orange, which binds specifically to DNA thus allowing a clear visualization of the nuclei under the fluorescent laser. Images are obtained in a haematoxylin and eosin (H&E) digital staining, which facilitates the interpretation by pathologists and surgeons. CFM has been approved for clinical use in gastroenterology and pulmonology, specifically for the evaluation of Barrett’s oesophagus, pancreaticobiliary diseases, gastric cancer, and other pathological conditions
[3][4][5]. It has also been applied in dermatology, where it is currently used to determine positive margins of basal cell and squamous cell carcinoma during Mohs surgery
[6].
The use of fluorescence confocal microscopy is also spreading in urological practice. Over the last ten years various applications have been explored in a bid to validate a useful diagnostic tool able to aid both intraoperative decision making and office followup
[7][8].
Considering the urothelial carcinoma (UC) scenario, FCM has been investigated in both bladder cancer (BC) and upper-tract urothelial carcinoma (UTUC). Confocal laser endomicroscopy (CLE) is a unique optical imaging technology that can provide real-time and high-resolution imaging of the cellular architecture and the morphology of mucosal lesions. Its use during transurethral resection of bladder tumours (TURBT) or cystoscopy provides the surgeon with useful histological information and represents a promising technique for conservative BC management
[9][10][11]. CLE is a reliable and accurate technique in BC diagnosis
[12]. Furthermore, CLE can be performed in patients with UTUC during ureteroscopy
[13]. In regard to prostatic specimens’ interpretation, CFM has been applied both in the office setting to study biopsy cores as well as intraoperatively to evaluate surgical margins during radical prostatectomy
[14][15]. CFM has also been successfully applied for a real-rime diagnosis of renal cell carcinoma (RCC)
[16].
2. Fluorescence Confocal Microscopy in Urological Malignancies
2.1. Bladder Cancer
BC is a heterogeneous disease encompassing non-muscle-invasive (NMIBC) and muscle-invasive BC (MIBC) and entailing very heterogeneous managements and prognoses
[17][18][19][20][21]. The results regarding CFM applications in BC detection are reported in
Table 1.
Table 1. Confocal microscopy in BC.
Author |
Year |
Pat. (n.) |
Setting |
CFM System |
Procedure |
Se. (%) |
Sp. (%) |
PPV (%) |
NPV (%) |
Main Outcomes |
Lee [22] |
2019 |
75 |
In vivo |
Cellvizio |
TURB |
91.7 (mal. vs. ben.)
94.5 (LGUC vs. HGUC)
71.4 (CIS vs. IT) |
73.9 (mal. vs. ben.)
66.7 (LGUC vs. HGUC)
81.3 (CIS vs. IT) |
93.6 (mal. vs. ben.)
89.7 (LGUC vs. HGUC)
83.3 (CIS vs. IT) |
68.0 (mal. vs. ben.)
80.0 (LGUC vs. HGUC)
68.4 (CIS vs. IT) |
CLE represents a promising technology to provide real-time reliable diagnosis and grading of UC. Moreover, it might improve RFS. |
Lucas [23] |
2019 |
53 |
In vivo |
Cellvizio + AI- image analysis |
TURB |
NR |
NR |
NR |
NR |
CLE accuracy regarding malignant vs. benign tissue distinction was 79%, while the HGUC vs. LGUC differentiation accuracy was 82%. |
Liem [24] |
2018 |
53 |
In vivo |
Cellvizio |
TURB |
76.0 (LGUC) vs. 70.0 (HGUC) |
76.0 (LGUC) vs. 69.0 (HGUC) |
NR |
NR |
Concordance between CLE-based classification and final histopathology was found in 19 LGUC cases (76%), 19 HGUC cases (70%), and 4 benign lesion cases (29%). |
Chang [10] |
2013 |
31 |
Ex vivo |
NR |
TURB |
50.0 (LGUC) vs. 75.0 (HGUC) |
94.0 (LGUC) vs. 64.0 (HGUC) |
NR |
NR |
Novice CLE observers achieved a diagnostic accuracy comparable to WLC-images-only observation after a short training. An expert CLE observer achieved higher accuracy rates compared to WLC-image-only analysis. |
This entry is adapted from the peer-reviewed paper 10.3390/life13122301